艾司西酞普兰联合度洛西汀治疗伴有躯体症状抑郁症患者的疗效

Efficacy of escitalopram combined with duloxetine in the treatment of depression patients with somatization

目的探讨艾司西酞普兰联合度洛西汀治疗伴有躯体症状的抑郁症患者的疗效。方法选取河南省某医院2019年10月-2020年12月收治的100例伴有躯体症状的抑郁症患者,采用随机数字表法分为对照组(46例)和观察组(54例)。对照组患者采用度洛西汀治疗,观察组患者采用艾司西酞普兰联合度洛西汀治疗,比较2组患者的临床疗效、不良反应发生情况,治疗前后健康状况调查简表(SF-36)及健康问卷躯体症状群量表(PHQ-15)评分。结果观察组患者治疗总有效率为96.30%,高于对照组的80.43%,差异有统计学意义(χ^(2)=6.383,P=0.012)。治疗后,2组患者SF-36各维度评分均高于治疗前,且观察组高于对照组,差异均有统计学意义(P<0.05)。治疗后,2组患者PHQ-15评分低于治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05)。观察组患者不良反应发生率为20.37%,低于对照组的32.61%,但差异无统计学意义(χ^(2)=1.934,P=0.164)。结论艾司西酞普兰联合度洛西汀治疗伴有躯体症状的抑郁症患者,疗效较好,有助于提高患者生活质量,减轻躯体症状。

Objective To investigate the efficacy of escitalopram combined with duloxetine in the treatment of depression patients with somatization. Methods A total of 100 depression patients with somatic symptoms in a hospital in Henan Province from October 2019 to December 2020 were randomly divided into control group(n=46) and observation group(n=54). The patients in the control group were treated with duloxetine, and the patients in the observation group were treated with escitalopram combined with duloxetine. The clinical efficacy, adverse reactions, Short Form-36 Health Status Questionnaire(SF-36) before and after treatment and Health Questionnaire-15(PHQ-15) were compared between the two groups. Results The total effective rate of patients in the observation group was 96.30%, which was lower than that in the control group(80.43%), and the difference was statistically significant(χ^(2)=6.383,P=0.012). After treatment, the scores of all dimensions of SF-36 in the two groups were higher than those before treatment, and those in the observation group were higher than those in the control group, and the differences were statistically significant(P <0.05). After treatment, the PHQ-15 score of the two groups was lower than that before treatment, and that of the observation group was lower than that of the control group, and the difference was statistically significant(P<0.05). The incidence of adverse reactions in the observation group was 20.37%, which was higher than that in the control group(32.61%), but the difference was not statistically significant(χ^(2)=1.934, P=0.164). Conclusion Escitalopram combined with duloxetine is effective in the treatment of depression patients with somatization, which is helpful to improve the quality of life and alleviate somatization.